T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs)

Haematology has been at the vanguard of cancer immunotherapy. Immune checkpoint inhibitors (ICIs), bispecific T-cell engagers (BiTEs), allogeneic haematopoietic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI), as well adoptive therapies outside setting allo-HSCT, have approved for distinct haematologic malignancies producing durable responses in otherwise untreatable patients. Despite recent advances, immunotherapies do not benefit most patients, due to resistance or lack response, are only specific settings. Moreover, expensive may produce severe immune related adverse reactions. Combination therapy complicates picture requires further evaluation. This review considers current status future perspectives ICIs BiTEs haematological by analysing their strengths, weaknesses, opportunities threats (SWOT). The biological rationale anti-cancer mechanisms, clinical data cancers, efficacy, toxicity, response profiles, novel strategies improve these characteristics potential targets enhance expand application also discussed.